Quick answers
- What is Methocarbamol used for?
- The FDA-approved label (Robaxin, Hikma Pharmaceuticals USA Inc., April 10, 2024) says: “The injectable form of methocarbamol is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Methocarbamol does not directly relax tense skeletal muscles in man.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Methocarbamol have a boxed warning?
- No. None of the 168 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Methocarbamol?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Methocarbamol been recalled?
- FDA enforcement reports list 2 recalls of products of this medicine; the newest started March 21, 2025 (Class II). A recall usually concerns specific lots, not every product.
- Who makes Methocarbamol?
- 64 companies list prescription products of Methocarbamol in the FDA NDC Directory, including Bryant Ranch Prepack, A-S Medication Solutions and PD-Rx Pharmaceuticals, Inc..
What Methocarbamol is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
The injectable form of methocarbamol is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Methocarbamol does not directly relax tense skeletal muscles in man.
— FDA label: Robaxin, Hikma Pharmaceuticals USA Inc., effective April 10, 2024. Read the full label on DailyMed →
The FDA has 168 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 168 FDA labels for this medicine have a boxed warning.
Forms and how it is given
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| methocarbamol 1000 mg tablet, coated | Generic | $8.35 per tablet |
| methocarbamol 1000 mg tablet, film coated | Generic | $8.35 per tablet |
| methocarbamol 500 mg tablet | Generic | $0.0386 per tablet |
| methocarbamol 500 mg tablet, coated | Generic | $0.0386 per tablet |
| methocarbamol 500 mg tablet, film coated | Generic | $0.0386 per tablet |
| methocarbamol 750 mg tablet | Generic | $0.0441 per tablet |
| methocarbamol 750 mg tablet, coated | Generic | $0.0441 per tablet |
| methocarbamol 750 mg tablet, film coated | Generic | $0.0441 per tablet |
NADAC list of November 4, 2026; these prices took effect between May 20, 2026 and October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Bryant Ranch Prepack24 products
- A-S Medication Solutions17 products
- PD-Rx Pharmaceuticals, Inc.14 products
- Proficient Rx LP12 products
- Asclemed USA, Inc.11 products
- Preferred Pharmaceuticals Inc.8 products
- Aphena Pharma Solutions - Tennessee, LLC7 products
- NuCare Pharmaceuticals, Inc.6 products
- Advanced Rx of Tennessee, LLC6 products
- St. Mary's Medical Park Pharmacy5 products
- Remedyrepack Inc.5 products
- Phoenix RX LLC4 products
- Cardinal Health 107, LLC4 products
- Coupler LLC4 products
- Advanced Rx Pharmacy of Tennessee, LLC4 products
- Northwind Health Company, LLC4 products
- Bostal LLC3 products
- Hawaii Repack, Inc.3 products
- Redpharm Drug3 products
- Direct_Rx3 products
- NCS HealthCare of KY, LLC dba Vangard Labs2 products
- Sagent Pharmaceuticals2 products
- Granulation Technology, Inc.2 products
- Major Pharmaceuticals2 products
- AvPAK2 products
- Aurobindo Pharma Limited2 products
- Granules India Ltd2 products
- Oxford Pharmaceuticals, LLC2 products
- Doc Rx2 products
- XLCare Pharmaceuticals, Inc.2 products
- Marlex Pharmaceuticals, Inc.2 products
- Camber Pharmaceuticals, Inc.2 products
- American Health Packaging2 products
- Key Therapeutics2 products
- Medcore LLC2 products
- Solco Healthcare LLC2 products
- Unichem Pharmaceuticals (USA), Inc.2 products
- Unit Dose Solutions, Inc.2 products
- Granules Pharmaceuticals Inc.2 products
- Golden State Medical Supply, Inc.2 products
- Hikma Pharmaceuticals USA Inc.2 products
- Trifluent Pharma, LLC1 product
- Somerset Therapeutics, LLC1 product
- Henry Schein, Inc.1 product
- Pharmasource Meds, LLC1 product
- Jvet Pharmaceuticals LLC1 product
- Regimed Medical1 product
- Eugia US LLC1 product
- Rosemont Pharmaceuticals LLC1 product
- Gland Pharma Limited1 product
- Slate Run Pharmaceuticals, LLC1 product
- Meitheal Pharmaceuticals Inc.1 product
- Medsource Pharmaceuticals1 product
- Fresenius Kabi USA, LLC1 product
- RedPharm Drug, Inc.1 product
- Baxter Healthcare Corporation1 product
- Oncora Pharma, LLC1 product
- Gentex Pharma, LLC1 product
- Dr.Reddys Laboratories Inc1 product
- Forte Bio-Pharma1 product
- FH2 Pharma LLC1 product
- DirectRx1 product
- Sportpharm LLC1 product
- Misemer Pharmaceutical1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA011790 ROBAXIN | Hikma | June 10, 1959 | 23, latest August 12, 2014 2014: Manufacturing (CMC) · 2014: Manufacturing (CMC) · 2004: Labeling |
| NDA219843 ATMEKSI | Rosemont Pharms | July 30, 2025 | — |
Generic approvals (18)
- ANDA086988Prinston Inc · October 29, 1979
- ANDA040489Oxford Pharms · January 29, 2003
- ANDA090200Hetero Labs Ltd III · November 6, 2009
- ANDA200958Bostal · October 21, 2011
- ANDA206128Eugia Pharma · May 27, 2016
- ANDA208116Hainan Poly · January 19, 2017
- ANDA203550Pharmobedient · February 8, 2017
- ANDA205404Sagent Pharms Inc · July 18, 2017
- ANDA208507Regcon Holdings · July 21, 2017
- ANDA207522Somerset Theraps LLC · July 31, 2017
- ANDA209331Fresenius Kabi USA · April 17, 2018
- ANDA209312Granules · May 7, 2018
- ANDA211504Gland · October 26, 2018
- ANDA213967Aurobindo Pharma Ltd · August 12, 2020
- ANDA212623Pharmazone · April 30, 2021
- ANDA215065Baxter Hlthcare Corp · July 14, 2022
- ANDA212707Pharmobedient · June 12, 2023
- ANDA086989—
Shortage status
The FDA drug shortage list does not show these products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
March 21, 2025 · Class II · Ongoing · D-0354-2025
Lack of Assurance of Sterility: Media fill with bacterial contamination
Methocarbamol Injection USP 1,000 mg/10 mL (100 mg/mL), 10 mL Single Dose Vial, Rx Only, Manufactured for: Somerset Therapeutics, LLC, Somerset, NJ 08873, NDC 70069-101-25 (immediate carton) and 70069-101-05 (5x10 mL car — Somerset Therapeutics Private Limited
-
February 15, 2024 · Class I · Ongoing · D-0440-2024
Presence of Particulate Matter
Methocarbamol Injection, USP 1000mg/10mL, (100mg/mL), 10 mL Single-Dose Vial packed 25 vials per carton, Rx Only, Mfd. in India for: Eugia US LLC. E. Windsor, NJ 08520, NDC 55150-223-10 — Eugia US LLC
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Robaxin, Hikma Pharmaceuticals USA Inc., effective April 10, 2024; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →